Home Alzheimer’s disease drug shows positive clinical trial results
News and Views

Alzheimer’s disease drug shows positive clinical trial results

Crystal Graham
alzheimers
(© Orawan – stock.adobe.com)

BrightFocus Foundation is encouraged by the positive topline results issued on the global Phase 3 clinical trial of Alzheimer’s drug lecanemab, which was reported to slow cognitive decline among people with Alzheimer’s disease.

The findings are the first to show a statistically significant decrease in cognitive issues by targeting amyloid, a protein expressed in many different organ systems.

The data, said Jim Taylor, president of Voice of Alzheimer’s, is another powerful sign of progress in the development of disease-modifying treatments for Alzheimer’s and additional evidence that the Centers for Medicare and Medicaid Services must rethink its blanket refusal to cover the new drugs.

“The companies described their test results as highly statistically significant,” said Taylor. “They are also politically significant. Based on these results, we will demand that the federal government change its unfair policies on coverage of Alzheimer’s treatments.”

Eisai and Biogen reported lecanemab reduced cognitive decline by 27 percent through the removal of aggregated amyloid-beta (Aβ ) in the brains of people who received it (nearly 2,000 participants) compared to a placebo.

When amyloid gets misprocessed and accumulates, it causes neurodegeneration. A healthy brain can break down amyloid-beta and eliminate it, but in Alzheimer’s disease, Aβ forms insoluble plaques that are toxic to neurons and sometimes associated with memory loss and other changes.

“BrightFocus Foundation is excited for a potential new treatment that could slow the progression of Alzheimer’s disease and improve quality of life for the millions of people it devastates,” said Stacy Pagos Haller, President and CEO, BrightFocus Foundation, in a news release. “Our team of expert Alzheimer’s disease researchers are actively exploring multiple scientific pathways that have the most promise to end Alzheimer’s; we won’t stop until there’s a cure.”

Eisai will present the study results on Nov. 29 at the Clinical Trials on Alzheimer’s Congress and stated that findings will be published in a peer-reviewed medical journal soon.

Eisai applied for accelerated FDA approval of the drug based on a smaller, earlier-stage clinical trial and said they will now submit the new trial results to the FDA. A decision on the drug should be made by early next year.

Voices of Alzheimer’s strongly urged the FDA to give prompt consideration of the newest data and urged speedy approval of the drug, according to a news release from the advocacy organization.

“The Alzheimer’s community has been praying for a successful result and our prayers have been answered,” said Terrie Montgomery, a founding board member of Voices of Alzheimer’s who is living with early-onset Alzheimer’s. “We will now turn our attention to our elected leaders and demand that lecanemab and similar treatments, once approved by the FDA, be covered by Medicare and Medicaid to make them accessible to the people who need them.”

Once the FDA makes a decision.  the drug would go to the Centers for Medicare and Medicaid for a coverage decision.

“It is our strong belief that Medicare has discriminated against people with Alzheimer’s and their families for the last decade by failing to provide coverage for Alzheimer’s diagnostics and FDA-approved treatments,” said Phil Gutis, a founding VOA Board member and person living with early-onset Alzheimer’s. “All people living with Alzheimer’s and their families must let the government know in no uncertain terms that such discrimination is unacceptable and must end.”

Learn more about the results online at brightfocus.org.

Learn more about Voices of Alzheimer’s and their advocacy efforts at voicesofad.com

 

Support AFP

Newsletter

Featured Video

 

 




Crystal Graham

Crystal Graham

Crystal Graham is the digital editor and development director for Augusta Free Press. A 1999 graduate of Virginia Tech, Crystal has worked for 25 years as a reporter and editor for several Virginia publications, written a book, and garnered more than a dozen Virginia Press Association awards for writing and graphic design. She was the co-host of "Viewpoints," a weekly TV news show, and co-host of "Virginia Tonight," a nightly TV news show, both broadcast on PBS. Her work on "Virginia Tonight" earned her a national Telly award for excellence in television. She also has a strong development background as the former director in Virginia for a national suicide prevention organization. You can reach her at [email protected]. Support AFP by signing up for our newsletter and/or powering our work with a one-time or monthly contribution.

Latest News

uva basketball swish
Basketball, Go 'Hoos

Live Coverage: #4 Virginia hosts ODU in battle of 5-0 in-state teams

ben cline
Politics, Virginia

Ben Cline announces series of town halls, with a catch, in the form of a waitlist

Ben Cline is catching heat, and rightly so, for announcing today that he will be participating in town halls in Waynesboro, Roanoke and Harrisonburg that are scheduled for Monday, Nov. 23, that, within minutes of the announcement, were listed as “sold out.”

waynesboro map
Local

Waynesboro PD still mum on Sept. 2 school shooting: Do we need to fire somebody over this?

Waynesboro Police are, still, not answering questions about the Sept. 2 shooting at Westwood Hills Elementary School, in which a former student took his own life in the school library.

measles illustration
Local

Virginia Department of Health confirms local measles case, warns of possible exposure

suicide death mental health depression candle
Local

A father writes about his daughter’s death by suicide: Don’t let the conversation end

uva nov 13 graphic
Football, Go 'Hoos

The Nov. 13 Record: UVA alumni group sheds light on what the school knew

uva football kam robinson INT
Football, Go 'Hoos

ACC Football: UVA linebacker Kam Robinson among the Players of the Week